IL316308A - Modifying binding molecules to minimize pre-existing interactions - Google Patents
Modifying binding molecules to minimize pre-existing interactionsInfo
- Publication number
- IL316308A IL316308A IL316308A IL31630824A IL316308A IL 316308 A IL316308 A IL 316308A IL 316308 A IL316308 A IL 316308A IL 31630824 A IL31630824 A IL 31630824A IL 316308 A IL316308 A IL 316308A
- Authority
- IL
- Israel
- Prior art keywords
- level
- seq
- monoclonal antibody
- subject
- component
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695988P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/041203 WO2020014358A1 (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316308A true IL316308A (en) | 2024-12-01 |
Family
ID=67544330
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316308A IL316308A (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
| IL279803A IL279803A (en) | 2018-07-10 | 2020-12-27 | Modifying binding compounds to minimize given interactions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279803A IL279803A (en) | 2018-07-10 | 2020-12-27 | Modifying binding compounds to minimize given interactions |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11448651B2 (enExample) |
| EP (1) | EP3820891A1 (enExample) |
| JP (2) | JP7665339B2 (enExample) |
| KR (1) | KR102938177B1 (enExample) |
| CN (1) | CN112543768B (enExample) |
| AR (1) | AR115730A1 (enExample) |
| AU (1) | AU2019302642B2 (enExample) |
| BR (1) | BR112020026784A2 (enExample) |
| CA (1) | CA3104873A1 (enExample) |
| EA (1) | EA202190228A1 (enExample) |
| IL (2) | IL316308A (enExample) |
| MX (2) | MX2021000239A (enExample) |
| MY (1) | MY202673A (enExample) |
| SG (1) | SG11202012835RA (enExample) |
| TW (2) | TWI838388B (enExample) |
| WO (1) | WO2020014358A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR115730A1 (es) | 2018-07-10 | 2021-02-17 | Regeneron Pharma | Modificación de moléculas de unión para minimizar interacciones pre-existentes |
| US20260008857A1 (en) * | 2024-06-13 | 2026-01-08 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2006526414A (ja) | 2003-06-02 | 2006-11-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 脱免疫化抗ｃｄ３抗体 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2009091240A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| AU2009303318B2 (en) * | 2008-10-10 | 2016-06-30 | Aptevo Research And Development Llc | TCR complex immunotherapeutics |
| CA2741114A1 (en) | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| WO2010122148A1 (en) | 2009-04-24 | 2010-10-28 | Boehringer Ingelheim International Gmbh | An improved antibody domain and antibody fragments and antibodies based thereon |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011074965A1 (en) | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| WO2012166588A2 (en) | 2011-06-01 | 2012-12-06 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| HK1220465A1 (zh) * | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| TWI633891B (zh) * | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| US9951141B2 (en) * | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| EP3200823B1 (en) | 2014-10-02 | 2022-11-23 | City of Hope | Multivalent meditopes, meditope-binding antibodies and uses thereof |
| MX2017005156A (es) * | 2014-11-05 | 2017-08-08 | Hoffmann La Roche | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. |
| AU2015346150B2 (en) | 2014-11-14 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2017072210A1 (en) * | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
| AU2016344133A1 (en) | 2015-10-30 | 2018-05-17 | Genentech, Inc. | Anti-Factor D antibody formulations |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| EP3713966A1 (en) | 2017-11-22 | 2020-09-30 | Vacara AB | Antibodies to citrullinated proteins |
| AR115730A1 (es) | 2018-07-10 | 2021-02-17 | Regeneron Pharma | Modificación de moléculas de unión para minimizar interacciones pre-existentes |
| WO2020246891A1 (en) | 2019-06-07 | 2020-12-10 | Sanquin Innovatie B.V. | Methods and compounds for typing rheumatoid factors |
-
2019
- 2019-07-10 AR ARP190101943A patent/AR115730A1/es unknown
- 2019-07-10 SG SG11202012835RA patent/SG11202012835RA/en unknown
- 2019-07-10 JP JP2020572773A patent/JP7665339B2/ja active Active
- 2019-07-10 IL IL316308A patent/IL316308A/en unknown
- 2019-07-10 CA CA3104873A patent/CA3104873A1/en active Pending
- 2019-07-10 CN CN201980042886.7A patent/CN112543768B/zh active Active
- 2019-07-10 EA EA202190228A patent/EA202190228A1/ru unknown
- 2019-07-10 AU AU2019302642A patent/AU2019302642B2/en active Active
- 2019-07-10 TW TW108124293A patent/TWI838388B/zh active
- 2019-07-10 BR BR112020026784-8A patent/BR112020026784A2/pt unknown
- 2019-07-10 US US16/507,880 patent/US11448651B2/en active Active
- 2019-07-10 WO PCT/US2019/041203 patent/WO2020014358A1/en not_active Ceased
- 2019-07-10 KR KR1020217002619A patent/KR102938177B1/ko active Active
- 2019-07-10 MY MYPI2020006898A patent/MY202673A/en unknown
- 2019-07-10 MX MX2021000239A patent/MX2021000239A/es unknown
- 2019-07-10 EP EP19749878.5A patent/EP3820891A1/en active Pending
- 2019-07-10 TW TW113110335A patent/TW202428612A/zh unknown
-
2020
- 2020-12-27 IL IL279803A patent/IL279803A/en unknown
-
2021
- 2021-01-07 MX MX2025013509A patent/MX2025013509A/es unknown
-
2022
- 2022-09-19 US US17/933,185 patent/US12523659B2/en active Active
-
2025
- 2025-04-09 JP JP2025064335A patent/JP2025100662A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202428612A (zh) | 2024-07-16 |
| US11448651B2 (en) | 2022-09-20 |
| KR20210030378A (ko) | 2021-03-17 |
| TW202021984A (zh) | 2020-06-16 |
| CA3104873A1 (en) | 2020-01-16 |
| MY202673A (en) | 2024-05-14 |
| AU2019302642A1 (en) | 2021-02-25 |
| JP2021531245A (ja) | 2021-11-18 |
| AR115730A1 (es) | 2021-02-17 |
| US12523659B2 (en) | 2026-01-13 |
| SG11202012835RA (en) | 2021-01-28 |
| EP3820891A1 (en) | 2021-05-19 |
| TWI838388B (zh) | 2024-04-11 |
| MX2025013509A (es) | 2025-12-01 |
| MX2021000239A (es) | 2021-03-25 |
| US20200018754A1 (en) | 2020-01-16 |
| JP2025100662A (ja) | 2025-07-03 |
| US20230266333A1 (en) | 2023-08-24 |
| IL279803A (en) | 2021-03-01 |
| CN112543768A (zh) | 2021-03-23 |
| WO2020014358A1 (en) | 2020-01-16 |
| EA202190228A1 (ru) | 2021-04-14 |
| KR102938177B1 (ko) | 2026-03-11 |
| BR112020026784A2 (pt) | 2021-03-30 |
| JP7665339B2 (ja) | 2025-04-21 |
| AU2019302642B2 (en) | 2025-10-30 |
| CN112543768B (zh) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110832327A (zh) | 诊断性晚期糖基化终末产物抗体 | |
| JP2018520668A5 (enExample) | ||
| CN109311983B (zh) | 人源化抗clever-1抗体及其用途 | |
| RU2013141134A (ru) | Антитела, которые специфично связывают альфа-токсин staphylococcus aureus, и способы их применения | |
| JP2014521089A5 (enExample) | ||
| JP5305903B2 (ja) | 感染症の検出方法 | |
| JP6564435B2 (ja) | アルファ４ベータ７ヘテロ二量体特異抗体の投与 | |
| Costa et al. | Diagnosis of human strongyloidiasis: Application in clinical practice | |
| IL316308A (en) | Modifying binding molecules to minimize pre-existing interactions | |
| US20230266341A1 (en) | Method for diagnosis based on circulating extracellular vesicles | |
| JP2014515740A5 (enExample) | ||
| JP2015520608A5 (enExample) | ||
| Sung et al. | Prediction of functional outcome in axonal Guillain-Barre syndrome | |
| JP2021531245A5 (enExample) | ||
| Lucendo et al. | Emerging therapeutic strategies for eosinophilic esophagitis | |
| JP2022547993A5 (enExample) | ||
| JP2022538688A5 (enExample) | ||
| WO2017149122A1 (en) | Clinical assessment of m-protein response in multiple myeloma | |
| KR102626197B1 (ko) | 항 약물 항체의 수준을 정확하게 정량화하는 방법 | |
| JP2014515743A (ja) | Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 | |
| WO2021033196A1 (en) | Methods, compositions and kits for snake venom detection | |
| JP2021522478A (ja) | 選択された患者の心血管疾患を治療するための組成物および方法 | |
| JP2008538508A5 (enExample) | ||
| JP2025506203A5 (enExample) | ||
| RU2019122099A (ru) | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile |